JBI-778

DRUG2 trials

Sponsors

Jubilant Therapeutics Inc., Jubilant Therapeutics India Limited

Conditions

Adenoid Cystic Carcinoma MetastaticAdenoid Cystic Carcinoma of the Head and NeckBrain Metastases From Solid TumorsGlioblastoma (GBM)High Grade Glioma (HGG)Leptomeningeal DiseaseNSCLC Patients With EGFR Activating Mutation

Phase 1

Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma

Not yet recruitingNCT07751744

Jubilant Therapeutics Inc.Brain Metastases From Solid Tumors, Glioblastoma (GBM), High Grade Glioma (HGG) +1

Start: 2028-04-01End: 2030-03-31Target: 113Updated: 2026-08-07

First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

RecruitingNCT07755397

Jubilant Therapeutics India LimitedAdenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck, NSCLC Patients With EGFR Activating Mutation

Start: 2024-08-26End: 2028-04-01Target: 30Updated: 2026-08-10